Overview
Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-receptor blockers (ARB) are the most commonly prescribed anti-hypertensive medications in the United States, yet whether ACEI or ARB use is associated with a greater risk of hyperkalemia remains uncertain. Using real-world evidence from electronic health records, our study demonstrates that treatment with ACEI is associated with both a higher incidence and greater degree of hyperkalemia than treatment with ARB in adjusted models, especially in patients with chronic kidney disease. Providers should therefore consider this possible difference in hyperkalemia risk when choosing between ACEI and ARB therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Derington CG, King JB, Herrick JS, Shimbo D, Kronish IM, Saseen JJ, et al. Trends in antihypertensive medication monotherapy and combination use among US adults, NHANES 2005-2016. Hypertension. 2020;75:973–81.
Sadjadi SA, McMillan JI, Jaipaul N, Blakely P, Hline SS. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag. 2009;5:547–52.
Loutradis C, Price A, Ferroo CJ, Sarafidis P. Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. J Hum Hypertens. 2021;35:499–509.
Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int. 2000;58:2084–92.
Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010;5:531–48.
Jun HR, Kim H, Lee SH, Cho JH, Lee H, Yim HW, et al. Onset of hyperkalemia following the administration of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. Cardiovasc Ther. 2021;22:5935149.
Fang G, Annis IE, Farley JF, Mahendraratnam N, Hickson RP, Sturmer T, et al. Incidence of and risk factors for severe adverse events in elderly patients taking angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers after an acute myocardial infarction. Pharmacotherapy. 2018;38:29–41.
Epstein M, Lifschitz MD. Potassium homeostasis and dyskalemias: the respective roles of renal, extrarenal, and gut sensors in potassium handling. Kidney Int Suppl. 2016;6:7–15.
Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, et al. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project. J Am Heart Assoc. 2017;6:e005428.
Murray E, Reaven NL, Funk SE, McCaughey KJ, Oestreicher, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21:S212–20.
Preston RA, Baltodano NM, Alonso AB, Epstein M. Comparative effects on dynamic renal potassium excretion of ACE inhibitor versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus. J Clin Pharm. 2002;42:754–61.
Okada M. Big data and real-world data-based medicine in the management of hypertension. Hypertens Rev. 2021;44:147–53.
Gumz ML, Rabinowitz L. Role of circadian rhythms in potassium homeostasis. Semin Nephrol. 2013;33:229–36.
Funding
Dr. McCoy is supported by NINR R21-NR018738.
Author information
Authors and Affiliations
Contributions
JRS was responsible for preparing the manuscript and contributed to the design of the study protocol and data interpretation. SBG was responsible for conducting the data analysis, provided critical review of the manuscript, and contributed to data interpretation. THM was responsible for designing the study protocol, provided critical review of the manuscript, and contributed to data interpretation.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Salik, J.R., Golas, S.B. & McCoy, T.H. A comparative study assessing the incidence and degree of hyperkalemia in patients on angiotensin-converting enzyme inhibitors versus angiotensin-receptor blockers. J Hum Hypertens 36, 485–487 (2022). https://doi.org/10.1038/s41371-021-00625-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41371-021-00625-1